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Natriuretic Peptides in Common Valvular Heart Disease
Christopher D. Steadman, MB, CHB,* Simon Ray, MD,† Leong L. Ng, MD,* Gerry P. McCann, MD*
Leicester and Manchester, United Kingdom
Valvular heart disease, particularly aortic stenosis and mitral regurgitation, accounts for a large proportion of
cardiology practice, and their prevalence is predicted to increase. Management of the asymptomatic patient re-
mains controversial. Biomarkers have been shown to have utility in the management of cardiovascular disease
such as heart failure and acute coronary syndromes. In this state-of-the-art review, we examine the current evi-
dence relating to natriuretic peptides as potential biomarkers in aortic stenosis and mitral regurgitation. The
natriuretic peptides correlate with measures of disease severity and symptomatic status and also can be used to
predict outcome. This review shows that natriuretic peptides have much promise as biomarkers in common val-
vular heart disease, but the impact of their measurement on clinical practice and outcomes needs to be further
assessed in prospective studies before routine clinical use becomes a reality. (J Am Coll Cardiol 2010;55:
2034–48) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.021N
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lurveillance of valvular heart disease accounts for a signif-
cant proportion of outpatient attendances in cardiology.
he predicted prevalence may double within 20 years due to
n aging population (1). Patient management usually in-
olves monitoring for clinical symptoms or functional dete-
ioration usually assessed by imaging studies, of which
ransthoracic echocardiography is the mainstay. A biomar-
er is defined as a biological molecule that can be identified
n a particular disease and additionally may be able to assess
he severity and prognosis or monitor the response to
reatment of that disease state. This is an attractive prospect
n valvular heart disease. A robust biomarker could poten-
ially eliminate the need for some costly imaging studies
uring routine surveillance and aid in management deci-
ions, particularly with regard to the optimum timing for
urgical or percutaneous intervention. Natriuretic peptides
re endogenous cardiac hormones and have shown utility as
iomarkers in heart failure, both for diagnosis (2) and to
onitor and guide therapy (3,4), and, in ischemic heart
isease, as a predictor of outcome (5–7). This review
xamines natriuretic peptides as potential biomarkers in the
ost commonly managed valvular heart diseases, aortic
tenosis (AS) and mitral regurgitation (MR).
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hree types of natriuretic peptides have been identified:
-type natriuretic peptide (BNP), atrial natriuretic peptide
ANP), and C-type natriuretic peptide (CNP). Their phys-
ology has been reviewed in detail elsewhere (8–11). Briefly,
NP is structurally distinct from ANP and BNP. CNP is
xpressed to a much greater extent in the central nervous
ystem and vascular tissues than in the heart (12), acting as
potent vasorelaxant and inhibitor of vascular smooth
uscle proliferation and endothelial cell migration (11).
NP and ANP exist as pro-hormones that are cleaved into
nactive N-terminal fragments (N-terminal proBNP [NT-
roBNP], N-terminal proANP [NT-proANP]) and bio-
ogically active hormones (BNP, ANP) before release into
he circulation. The N-terminal fragments are more stable
n vivo and are often used as surrogate markers for the
iologically active hormone (8). The predominant cardiac
ource of ANP is the atria and the ventricles are the main
ardiac source of BNP, although both can be synthesized in
ither chamber. ANP is stored in granules, whereas BNP is
eleased in bursts regulated by gene transcription (13–15)
he stimulus for ANP and BNP release is primarily
yocyte stretch, but endothelin-I, nitric oxide, and angio-
ensin II may all have a role. ANP concentrations are more
losely related to left atrial (LA) pressure and BNP to left
entricular (LV) pressure (16,17). Three natriuretic peptide
eceptors (NPRs) have been identified; NPR-A and
PR-B, which mediate their biological action, and
PR-C, which is a clearance receptor (18). Natriuretic
eptides cause natriuresis, diuresis, and vasorelaxation, re-
ucing blood pressure and preload (11). BNP has direct
usitropic (relaxing) properties in the myocardium (19).
NP and BNP have been shown in vitro to have the effect
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20,21). Additionally, natriuretic peptides, their processing
nzymes, and their receptors are expressed in the cardiac
alves themselves (22). The close links between natriuretic
eptides and cardiovascular structure, function, and hemo-
ynamics are clear; however, current understanding of the
olecular biology is far from complete (8).
ethods
systematic search of peer-reviewed literature until September
009 using PubMed was performed. The search terms “biomar-
ers,” “natriuretic peptide,” “BNP,” “NTproBNP,” “ANP,” and
CNP” were combined and then coupled with each of “aortic
tenosis” and “mitral regurgitation.”
Predefined limits were: 1) the main body of text of the article
eeded to be in English; 2) human adult subjects; 3) prospec-
ive, retrospective, and randomized studies were included; 4)
eviews and case reports or studies with 10 patients were
xcluded; and 5) only studies in which a group containing at
east mild isolated AS or isolated MR, which had been well
haracterized and specifically analyzed (primarily or as a
ubstudy), were included. Studies including patients with
ixed valve disease or severe valvular lesions in addition to
he valve lesion of interest were excluded. Studies were
ncluded irrespective of the presence of other comorbidities
ncluding coronary artery disease (CAD) and symptoms.
esults
n AS, 41 studies of natriuretic peptides were appropriate
or review. Details of the important studies are presented in
ables 1 through 3 for baseline correlations, unoperated,
nd post-operative outcome, respectively. In MR, 9 studies of
atriuretic peptides were appropriate for review. Details of
aseline correlations are given in Table 4, and predictors
f outcome are shown in Table 5.
For both valvular diseases, the studies reviewed have
ignificant clinical and methodological diversity, particularly
ith regard to measures of outcome. This heterogeneity
oes not lend itself to a meaningful meta-analysis, and
herefore we present a systematic review using a more
ualitative approach to combining results. Where the dis-
ribution of natriuretic peptide measurements is signifi-
antly skewed, they have been logarithmically transformed
n the original studies before analysis.
atriuretic Peptides in AS
linical decision making in AS. AS is the most common
alve lesion requiring surgery in the developed world (23).
he survival of patients with symptomatic AS is dismal, and
he prognosis is greatly improved by aortic valve replace-
ent (AVR), which is universally recommended (24). Inontrast, management of patients with moderate to severe isymptomatic AS is a controversial
rea and has been the subject of
ot debate among cardiologists
nd cardiac surgeons for40 years
25,26). Traditionally, the risk of
udden cardiac death in asymp-
omatic patients has been regarded
s low, typically 1% (27,28).
owever, rates of almost 5% per
ear have been reported where a
igid policy of not operating on
symptomatic patients was ad-
ered to (29). Additionally, with a
atchful waiting approach to
uide surgery, concerns include
atients not promptly seeking help
hen they become symptomatic
nd the risk of mortality while
waiting surgery when symptom-
tic (30). Over the past decade,
everal important prospective
tudies have been published on the
atural history of asymptomatic
S incorporating echocardio-
raphic measures of severity, func-
ional testing, the subsequent de-
elopment of symptoms, need for
VR, and death (27–29,31–34).
ven in research study popula-
ions, significant numbers under-
ent AVR while asymptomatic at
he discretion of the referring phy-
ician. These patients tended to be
lder and have more severe disease
27,28). This variation in clinical
ractice, along with differences
etween the American College
f Cardiology/American Heart
ssociation and the European
ociety of Cardiology guidelines
35,36), reflect the uncertainty regarding the best way to
anage these patients (37).
otential role of natriuretic peptides in valve disease. It
s clear from the currently available evidence that, in the
bsence of a randomized, controlled trial of surgery, better
isk stratification of asymptomatic patients with moderate to
evere AS and MR is still required, and biomarkers have a
ole to play. A useful biomarker would reflect disease
everity, increase with progression of disease, reflect sub-
linical myocardial dysfunction, discriminate between pa-
ients in whom symptoms do and do not develop in the
hort to medium term, and be easily and reliably measured.
he ideal biomarker would also allow the identification of a
igh-risk individual with severe disease before the develop-
ent of symptoms who could undergo valve surgery without
Abbreviations
and Acronyms
AF  atrial fibrillation
ANP  atrial natriuretic
peptide
AS  aortic stenosis
AUC  area under the
curve
AVA  aortic valve area
AVR  aortic valve
replacement
BNP  B-type natriuretic
peptide
CAD  coronary artery
disease
CNP  C-type natriuretic
peptide
LA  left atrial
LV  left ventricular
LVEF  left ventricular
ejection fraction
LVESVI  left ventricular
end-systolic volume index
LVMI  left ventricular
mass index
MACE  major adverse
cardiac event(s)
MR  mitral regurgitation
NPR  natriuretic peptide
receptor
NT-proANP  N-terminal
pro-atrial natriuretic
peptide
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Association
OR  odds rationcreased perioperative mortality.
Baseline Associations in ASTable 1 Baseline Associations in AS
Parameter First Author (Ref. #)/Year n Prospective BNP NT-proBNP ANP NT-proANP Statistical Methods
Aortic valve area Pedrazzini et al. (52)/2008 144 Yes Yes: lower with increasing tertile BNP,
p  0.016 (TTE)
Kruskal-Wallis
Cemri et al. (40)/2008 37 Yes Yes: r  0.46, p  0.008 (TTEi) Spearman correlation
Antonini-Canterin et al.
(46)/2008
64 Yes Yes: r  0.4, p  0.001 (TTE) Univariate regression analysis
Weber et al. (45)/2006 159 Yes Yes: r  0.380, p  0.001 (TTE) Spearman correlation
Neverdal et al. (44)/2006 22 Yes No: r  0.18, p  0.45 (TTE) Linear regression
Vanderheyden et al. (47)/
2004
40 Yes Yes: r  0.449, p  0.006 (TTE) Pearson correlation
Lim et al. (58)/2004 70 Yes Yes: r  0.49, p  0.0001 (TTE) Spearman correlation
Gerber et al. (48)/2003 74 Yes Yes: r  0.55, p  0.05 (TTE) Yes: r  0.57, p  0.05 (TTE) Yes: r  0.55, p  0.05 (TTE) Pearson correlation
Qi et al. (73)/2002 51 Yes Yes: r  0.46, p  0.037 (TTEi) Yes: r  0.49, p  0.023 (TTEi) Pearson correlation
Qi et al. (17)/2001 67 Yes Yes: r  0.56, p  0.001 (TTEi) Yes: r  0.52, p  0.001 (TTEi) Yes: r  0.33, p  0.05 (TTEi) Yes: r  0.47, p  0.001 (TTEi) Pearson correlation and
univariate linear
regression
Peak aortic valve
velocity
Neverdal et al. (44)/2006 22 Yes No: r  0.14, p  0.54 (TTE) Linear regression
Lim et al. (58)/2004 70 Yes Yes: r  0.33, p  0.05 (TTE) Spearman correlation
Weber et al. (61)/2004 146 Yes Weak: r  0.04, p  0.01 (TTE) Pearson correlation
Gerber et al. (48)/2003 74 Yes Yes: r  0.33, p  0.05 (TTE) Yes: r  0.35, p  0.05 (TTE) Yes: r  0.38, p  0.05 (TTE) Pearson correlation
Talwar et al. (39)/2001 15 Yes Yes: r  0.53, p  0.05 Pearson correlation
Prasad et al. (38)/1997 30 Yes Yes: r  0.43, p  0.02 (TTE) NS: r  0.31, p  0.1 (TTE) Univariate regression analysis
Mean aortic valve
gradient
Pedrazzini et al. (52)/2008 144 Yes No: 3 tertiles BNP, p  0.137 (TTE) Kruskal-Wallis
Orlowska-Baranowska
et al. (43)/2008
147 Yes Yes: r  0.25, p  0.002 (TTE) Linear regression
Cemri et al. (40)/2008 37 Yes Yes: r  0.38, p  0.026 (TTE) Spearman correlation
Antonini-Canterin et al.
(46)/2008
64 Yes No: r  0.08, p  0.52 (TTE) Univariate regression analysis
Weber et al. (45)/2006 159 Yes Yes: r  0.351, p  0.001 (TTE) Spearman correlation
Weber et al. (72)/2005 109 Yes Yes: severe  moderate  mild,
p  0.01 (TTE)
Kruskal-Wallis test
Weber et al. (61)/2004 146 Yes Yes: r  0.39, p  0.01 (TTE) Pearson correlation
Lim et al. (58)/2004 70 Yes Yes: r  0.34, p  0.004 (TTE) Spearman correlation
Gerber et al. (48)/2003 74 Yes Yes: r  0.36, p  0.05 (TTE) Yes: r  0.37, p  0.05 (TTE) Yes: r  0.38, p  0.05 (TTE) Pearson correlation
Qi et al. (17)/2001 67 Yes Yes: r  0.32, p  0.01 (TTE) Yes: r  0.25, p  0.05 (TTE) No : r  0.15 (TTE) No: r  0.09 (TTE) Pearson correlation and
univariate linear
regression
Prasad et al. (38)/1997 30 Yes Yes: r  0.57, p  0.001 (TTE) Yes: r  0.38, p  0.04 (TTE) Univariate regression analysis
Continued on next page
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he presence of AS almost universally has been associated
ith increased levels of natriuretic peptides when compared
ith controls (17,38,39), even in asymptomatic mild AS
40,41). This is supported by increased BNP messenger
NA in myocardial samples (42). The N-terminal forms
orrelate closely with the parent molecules as expected (17).
NP and ANP levels could also distinguish between AS
nd CAD patients undergoing cardiac surgery, with BNP
eing the better discriminator (41). BNP (43,44) and
T-proBNP (45) at baseline weakly but significantly cor-
elated with age.
EVERITY OF VALVE DISEASE. Natriuretic peptide levels
orrelate modestly with measures of AS severity on TTE.
here is a modest inverse correlation with aortic valve area
AVA) and a slightly weaker positive correlation with peak
nd mean pressure gradient in the majority of studies (Table 1,
ig. 1).
ARDIAC STRUCTURE AND FUNCTION. There is a signifi-
ant association between LV mass index (LVMI) and BNP
17,38,43,44,46–48) and NT-proBNP (17,40,45,48,49).
esults for ANP are variable, with some studies showing a
orrelation (17,48) and others not (39,41). NT-proBNP is
ignificantly increased relative to controls already in the
owest LVMI quartile (78 to 139 g/m2); in comparison,
T-proANP was increased over controls only from the
econd quartile (141 to 180 g/m2) and above (17).
The receiver-operator curve analyses in this study showed
hat BNP and NT-proBNP were most accurate in the
etection of increased LVMI, whereas NT-proANP per-
ormed best in the detection of increased LA pressure,
easured invasively (17). Thus, an elevation of BNP/NT-
roBNP levels in the circulation, with little or no increase in
NP/NT-proANP, may indicate a relatively early stage of
S, when LV hypertrophy compensates for the increase in
fterload without preload increase, whereas the combined
levation of both natriuretic peptides may indicate a more
dvanced stage. Right ventricular systolic pressure also
orrelates with BNP, NT-proBNP, and ANP (48). Of note,
ccentric LV hypertrophy was associated with a significantly
igher serum BNP level than concentric-type hypertrophy
44). Elsewhere, eccentric hypertrophy has been associated
ith the most impaired systolic function and the worst
linical picture, and it is postulated that this represents the
nd stage of pressure overload (50).
Natriuretic peptides correlate with markers of systolic
unction; BNP, ANP, and their N-terminal fragments
orrelate inversely with LVEF (43,45,46,48,51,52), and
ractional shortening (17,41). NT-proBNP also correlates
ith tissue Doppler imaging systolic velocity (53). Natri-
retic peptides also correlate with echocardiographic mea-
ures of diastolic function (46,48), although in the Gerber et
l. (48) study, the majority additionally had systolic dysfunc-
ion. The early diastolic transmitral velocity (E) correctedfor the influence of relaxation, the early diastolic velocity ofCo T
LV
A
N
P
tr
an
Unoperated Patients With ASTable 2 Unoperated Patients With AS
Outcome Measure
First Author
(Ref. #)/Year n Biomarkers Subjects
Other Valve
Disease CAD Comorbidities Design End Points Conclusions
Symptoms in
unoperated patients
Gerber et al. (66)/2005 29 NT-proBNP Asymptomatic, at least
mild AS (peak
velocity 2.5 m/s)
Excluded mild
MR or AR
Excluded MI
6 months,
RWMA,
previous
cardiac
surgery
Not reported Prospective cohort
mean follow-up
18 months
Symptoms developed
in 8 patients
NT-proBNP predicts
development of
symptoms;
OR  9.6 for
development of
symptoms if
NT-proBNP 50
pmol/l by
logistic
regression
Bergler-Klein et al. (51)/
2004
43 initially
asymptomatic
BNP, NT-
proBNP,
NT-proANP
Severe AS (peak
velocity 4 m/s or
AVA 1 cm2)
Excluded mild
MVD or AR
9%; not all had
angiography
67% HT Prospective cohort
follow-up 377 
150 days
14 patients developed
symptoms
NT-proBNP best
predicts
symptom-free
survival, also
BNP and
NT-proANP;
Kaplan-Meier
analysis
Survival without AVR Nessmith et al. (57)/
2005
103 total;
24 asymptomatic,
79 symptomatic
but unoperated
BNP AVA 1.2 cm2 Not reported Excluded MI 6
mo, RWMA,
previous
cardiac
surgery
83% HT,
27% DM
Prospective cohort
median follow-
up 227 days
44 deaths 1-year mortality RR
increased by 2.9
per tertile of
BNP (2.4 after
adjustment for
symptoms) by
Cox proportional
hazards method
MACE: death/symptom
or positive exercise
test results–driven
AVR
Monin et al. (69)/2009 107 BNP Asymptomatic AS
(mean peak velocity
4.1 m/s)
Excluded more
than mild
other valve
lesions
22%, not all had
angiography
56% HT, 12%
DM, all SR
Prospective cohort
follow-up
24 mo
3 deaths before AVR,
18 patients AVR
for positive ETT,
37 patients AVR
for symptoms,
4 patients AVR
physician
discretion
BNP independent
predictor of
outcome by
multiple logistic
regression model
MACE: CVS
death/hospitalization
for HF/AVR
Antonini-Canterin et al.
(46)/2008
64 BNP Mean AVA 0.9 cm2
(range 0.3–1.7 cm2);
no more than
mild AR
Did not exclude
other valve
disease;
severe MR
in 3
28%, not all had
angiography
55% HT, 17%
DM, 9% AF
Prospective cohort
median follow-
up 8 mo
Total MACE 18 (28%),
2 AVR, 7 CVS
deaths,
9 admission
with HF
BNP levels at
baseline
predicted event-
free survival by
Kaplan-Meier
analysis
MACE: cardiac death/
symptom-driven AVR
Poh et al. (55)/2008 53 NT-proBNP Variable degrees of AS Excluded mild
additional
valve disease
Known CAD
43%, not all
had
angiography
60% HT, 32%
DM, all SR
Prospective cohort
median follow-
up 35 mo
Total MACE 18 NT-proBNP
predicted end
point on
univariate
analysis
MACE: CVS
death/symptoms/
AVR
Dichtl et al. (68)/2008 47 NT-proBNP,
CRP
Asymptomatic patients,
at least mild calcific
AS (mean gradient
15 mm Hg, peak
velocity 2 m/s)
Excluded MS,
severe MR,
severe AR
No history of
CAD
50% HT, 13%
DM, 11% AF
Randomized trial
of atorvastatin
Total MACE 24 (51%) NT-proBNP
predicted MACE
by multiple
regression
analysis
MACE: CVS
death/hospitalization
for HF
Weber et al. (45)/2006 57 conservatively
managed
NT-proBNP Mild (MPG 30 mm
Hg), moderate
(30–50 mm Hg), or
severe (50 mm Hg)
AS, excluded
AR II
Excluded MR II 33% of
conservatively
managed, not
all had
angiography
11% AF Prospective cohort
mean follow-up
892 days
Total MACE 9 (16%),
5 deaths (9%),
4 admissions with
HF (7%)
NT-proBNP
independent
predictor of end
point on
multivariate Cox
regression
Continued on next page
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May 11, 2010:2034–48 Natriuretic Peptides in Valvular Heart Diseasehe mitral annulus (Em), the E/Em ratio, is a marker of
iastolic dysfunction (54). This correlates significantly with
T-proBNP in severe symptomatic AS (53) and better
ith NT-proBNP than AVA in mild to moderate AS (55)
nd also is the strongest correlate in asymptomatic patients
r  0.53, p  0.001) (40).
Wall stress is an important stimulus to natriuretic peptide
roduction. LV end-systolic midwall wall stress, calculated
y the method of Grossman et al. (56), highly correlated
ith BNP (r  0.96, p  0.0001) (41), ANP (41,48), and
T-proBNP (48), as did LV end-diastolic wall stress (47).
T-proBNP is significantly related to mean LV strain (r 
.61, p  0.001) (49).
YMPTOMATIC STATUS. BNP (46,48,51,57– 60), NT-
roBNP (45,48,51,60,61), and ANP (38,48) are higher in
ymptomatic than asymptomatic patients with AS. A mul-
ivariate logistic regression model including BNP levels and
VA revealed that only BNP values were predictive of
ymptomatic AS (odds ratio [OR]: 3.4; 95% confidence
nterval [CI]: 1.6 to 7.3; p  0.01) (58). NT-proBNP
emained higher in symptomatic patients after adjustment
or age, sex, creatinine level, AVA, and LVEF, a mean 1.74
imes higher (95% CI: 1.12 to 2.69, p  0.014). This held
rue even when the AVA was 1 cm2 (48), although
nother study suggests that only BNP, and not NT-
roBNP, was useful for those with severe AS (60).
In symptomatic patients, natriuretic peptides increase
ith New York Heart Association (NYHA) functional
lass, irrespective of the severity of the AS (38,45,46,48,61).
ifferentiating asymptomatic from minimally symptomatic
i.e., NYHA functional classes I and II) is more difficult,
ith one study showing a significant difference (58) and
nother not (51). BNP can identify with good diagnostic
ccuracy patients in NYHA functional class III to IV; the
rea under the receiver-operator curve was 0.78 (95% CI:
.66 to 0.87; best cutoff was 254.64 pg/ml) (46). In contrast
o NYHA functional class, angina and syncope do not seem
o be related to natriuretic peptides (46,48,58), highlighting
he possible different pathophysiologies of these symptoms
ompared with dyspnea.
ESPONSE TO EXERCISE. In asymptomatic or minimally
ymptomatic AS, higher plasma levels of BNP are a better
redictor of an abnormal blood pressure response to exercise
han echocardiographic measures of severity (62). In mod-
rate to severe asymptomatic AS, BNP was associated with
ower peak velocity of the mitral valve annulus on exercise
nd reduced exercise capacity compared with controls (63).
oth of these studies only included patients with LVEF
50%. Taken together, these reports suggest that ele-
ated BNP reflects a reduced myocardial functional
eserve and is therefore indicative of LV dysfunction with
xercise despite normal measures of systolic function atrest in asymptomatic AS.Co T M
M
A
F

H
T


re
Post-Operative Outcome in ASTable 3 Post-Operative Outcome in AS
Outcome Measure
First Author
(Ref. #)/Year
No. of Patients
With AS Biomarkers Subjects
Other Valve
Disease CAD Comorbidities Design Results Conclusions
Post-operative: survival/
symptoms/LVEF
Bergler-Klein et al.
(51)/2004
79 underwent AVR
(incidence of
comorbidities
refers to whole
group of 130
patients)
BNP, NT-
proBNP,
ANP, NT-
proANP
Severe AS (peak
velocity 4
m/s or AVA
1 cm2)
Excluded mild
MVD or AR
25% 62% HT Prospective cohort 8 deaths
(6 perioperative,
2 late),
71 survivors
(63 normal LVEF,
65 NYHA I–II)
NT-proBNP only independent
predictor of survival and
post-operative symptoms;
pre-operative LVEF and
NT-proBNP independently
predicts post-operative
LVEF by multivariate
analysis
Post-operative: mortality Pedrazzini et al. (52)/
2008
144 BNP Severe AS (peak
velocity 4
m/s, AVA
1 cm2)
Not reported 60 (42%)
patients had
concomitant
CABG
92% SR Prospective cohort:
patients with
symptomatic AS
referred for
AVR,
comparison of
logistic
Euroscore to
BNP; baseline,
1, and 3
months post-
AVR
assessment
with clinical
follow-up after
2 yrs
9 (6%) perioperative
deaths, overall
mortality:
16 (11%)
BNP predicts post-operative
survival by logistic and
Cox regression
Post-operative: AF Yilmaz et al. (75)/2006 22 NT-proANP Symptomatic AS Excluded mild
other valve
disease
6 (27%) had
concomitant
CABG
All SR Prospective cohort 9 patients had AF
after 2 months
NT-proANP at 2 mo post-
operatively independently
predicts AF
Post-operative:
symptoms of left- or
right-sided HF/
hypotension
Vanderheyden et al.
(47)/2004
40 BNP Symptomatic, at
least mild AS
(peak velocity
2.5 m/s)
Not reported Not reported All SR Prospective cohort:
patients
referred for
LRHC for
symptomatic
AS, followed up
until hospital
discharge post-
AVR
17 patients had
clinical
deterioration
BNP at baseline significantly
higher in patients with
clinical deterioration by
t test
Post-operative: CVS
death/hospitalization
for HF
Weber et al. (45)/2006 102 AVR NT-proBNP Mild (MPG 30
mm Hg),
moderate
(30–50 mm
Hg), or
severe (50
mm Hg) AS
Excluded
MR II
29% of AVR 15% AF Prospective cohort:
mean follow-up
901 days
Total MACE: 12
patients (12%),
8 deaths (8%),
4 admissions
with HF (4%)
NT-proBNP had no predictive
value for those
undergoing AVR
CABG  coronary artery bypass graft; LRHC  left-right heart catheterization; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association; other abbreviations as in Tables 1 and 2.
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May 11, 2010:2034–48 Natriuretic Peptides in Valvular Heart DiseaseAD. The prevalence of CAD in AS is significant and has
een reported as 50% (64). Unless coronary angiography
as been performed in all patients included in a study, the
xact prevalence is unclear; estimations are usually made on
aseline Associations in MRTable 4 Baseline Associations in MR
Parameter
First Author
(Ref. #)/Year n Etiology
MR severity
Severity Potocki et al. (93)/2009 144 Organic
RVolume Kerr et al. (92)/2008 33 Organic
Severity Dini et al. (87)/2007 207 Functional
RFraction Yusoff et al. (90)/2006 38 Organic
RFraction Detaint et al. (86)/2006 78 Both No a
EROA Detaint et al. (91)/2005 124 Organic r  0
VC width Sutton et al. (85)/2003 49 Organic r  0
Symptoms
NYHA II Potocki et al. (93)/2009 144 Organic
NHYA II Kerr et al. (92)/2008 33 Organic
NYHA II Shimamoto et al. (94)/2007 62 Organic p 
NYHA II Yusoff et al. (90)/2006 38 Organic
NYHA II Detaint et al. (86)/2006 78 Both p 
NYHA II Detaint et al. (91)/2005 124 Organic r  0
NYHA II Sutton et al. (85)/2003 49 Organic p 
LVEF Potocki et al. (93)/2009 144 Organic
Kerr et al. (92)/2008 33 Organic
Detaint et al. (86)/2006 78 Both r2 
Detaint et al. (91)/2005 124 Organic r  
Sutton et al. (85)/2003 49 Organic r  0
LV diastolic size
LVEDD Potocki et al. (93)/2009 144 Organic
LVEDVI Kerr et al. (92)/2008 33 Organic
LVEDVI Yusoff et al. (90)/2006 38 Organic
LVEDVI Detaint et al. (86)/2006 78 Both p 
LVEDVI Detaint et al. (91)/2005 124 Organic r  0
LVEDD Sutton et al. (85)/2003 49 Organic r  0
LV systolic size
LVESD Potocki et al. (93)/2009 144 Organic
LVESVI Kerr et al. (92)/2008 33 Organic
LVESVI Yusoff et al. (90)/2006 38 Organic
LVESVI Detaint et al. (86)/2006 78 Both r2 
LVESVI Detaint et al. (91)/2005 124 Organic r  0
LVESD Sutton et al. (85)/2003 49 Organic r  0
LA size
LAD Potocki et al. (93)/2009 144 Organic
LAAI Kerr et al. (92)/2008 33 Organic
LAV Detaint et al. (86)/2006 78 Both p 
LAV Detaint et al. (91)/2005 124 Organic r  0
LAD Sutton et al. (85)/2003 49 Organic r  0
Pulmonary artery
systolic pressure
Potocki et al. (93)/2009 144 Organic
Kerr et al. (92)/2008 33 Organic
Detaint et al. (86)/2006 78 Both p 
Detaint et al. (91)/2005 124 Organic r  0
Right ventricular systolic
pressure
Sutton et al. (85)/2003 49 Organic r  0
Systolic wall stress Yusoff et al. (90)/2006 38 Organic
Detaint et al. (86)/2006 78 Both r2 
Sutton et al. (85)/2003 49 Organic r  0
NOVA  analysis of variance; EROA  effective regurgitant orifice area; LA  left atrial; LAAI  l
eft ventricular end-diastolic diameter; LVEDVI left ventricular end-diastolic volume index; LVESD
egurgitant fraction; RVolume  regurgitant volume; VC  vena contracta; other abbreviations ashe basis of clinical history. This is reflective of the clinical eetting during the surveillance of asymptomatic patients
ith AS when the presence or absence of coexisting CAD
s unknown. In AS patients with associated CAD, there are
eports of increased BNP (52) and NT-proBNP (65) or no
P NT-proBNP ANP Statistical Method
r  0.18, p  0.03 Pearson
r  0.2, p  0.27 Spearman
p  0.0001 Kruskal-Wallis
r  0.46, p  0.003 Pearson
ion Univariate regression
 0.06 Linear regression
 0.0001 r  0.54, p  0.0001 r  0.37, p  0.009 Pearson
p  0.001 ANOVA
p  0.02 Linear regression
p  0.031 Linear regression
Not specified Linear regression
Linear regression
 0.0001 Linear regression
p  0.001 p  0.001 Linear regression
r  0.25, p  0.01 Pearson
r  0.23, p  0.93 Spearman
 0.001 Univariate regression
p  0.01 Linear regression
p  0.98 r  0.01, p  0.92 r  0.20, p  0.17 Pearson
r  0.12, p  0.15 Pearson
r  0.02, p  0.28 Spearman
r  0.46, p  0.003 Pearson
Univariate regression
 0.08 Linear regression
 0.20 r  0.17, p  0.26 r  0.13, p  0.37 Pearson
r  0.33, p  0.001 Pearson
r  0.19, p  0.31 Spearman
r  0.52, p  0.001 Pearson
 0.001 Univariate regression
 0.002 Linear regression
 0.16 r  0.16, p  0.27 r  0.16, p  0.26 Pearson
r  0.21, p  0.01 Pearson
r  0.42, p  0.02 Spearman
Univariate regression
 0.0001 Linear regression
 0.0001 r  0.66, p  0.0001 r  0.49, p  0.0004 Pearson
r  0.35, p  0.001 Pearson
r  0.53, p  0.002 Spearman
Univariate regression
 0.0001 Linear regression
 0.03 r  0.33, p  0.09 r  0.47, p  0.01 Pearson
r  0.34, p  0.048 Pearson
 0.0001 Univariate regression
 0.88 r  0.11, p  0.45 r  0.01, p  0.95 Pearson
l area index; LAD  left atrial diameter; LAV  left atrial volume; LV  left ventricular; LVEDD 
entricular end-systolic diameter; LVESVI left ventricular end-systolic volume index; RFraction
es 1 through 3.BN
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.17, p
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0.036
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.37, p
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0.4, p
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0.01
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0.01
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ot always well described, it is a potential confounding
actor and a recognized limitation when using biomarkers to
ssess AS.
rediction of outcome in unoperated patients. SYMPTOM
NSET. Asymptomatic patients in whom symptoms de-
elop during follow-up have higher levels of BNP (51),
T-proBNP (51,66), and NT-proANP (51) at baseline.
atients with at least mild AS and a plasma level of
T-proBNP that exceeded normal limits (50 pmol/l) at
utcome in MRTable 5 Outcome in MR
Outcome Measure
First Author
(Ref. #)/Year n Etiology
Baseline
Status
Death/CCF/LV
dysfunction
Pizarro et al. (89)/
2009
269 Organic Asymptomatic
Death/CCF Dini et al. (87)/
2008
207 Functional NYHA II–IV
Death/CCF Detaint et al.
(91)/2005
124 Organic NYHA I–IV
CF  congestive cardiac failure; HR  hazard ratio; other abbreviations as in Tables 1 through 4
Figure 1 NT-proBNP Levels According to Severity of AS
Values are mean  SEM. Aortic stenosis (AS) I  mild-moderate AS; AS II  mod
(AVA 0.7 cm2); AVR  AS patients who have had aortic valve replacement. Repraseline were more likely to have symptoms develop (55%)
han patients with levels of NT-proBNP within normal
imits (11%) (OR: 9.6, 95% CI: 2 to 64, p  0.02) (66).
VA, peak aortic velocity, and LVEF were less reliable
redictors of symptomatic onset (66). In severe AS,
ymptom-free survival at 3, 6, 9, and 12 months was best
eparated by NT-proBNP levels of 80 pmol/l versus 80
mol/l: 100% versus 92%, 88% versus 58%, 88% versus 35%,
nd 69% versus 18%, respectively (51). Those in whom
ymptoms developed did not differ significantly with regard
Design Biomarker End Points Conclusions
pective cohorts,
rivation, and
lidation; mean follow-
: 36 months
rivation,
months validation
BNP 21% in derivation,
20.6% in
validation
BNP 105 pg/ml
predicts death/
CCF/LV
dysfunction;
HR: 4.7 in
validation
cohort
pective cohort, median
llow-up 29 months
NT-proBNP 67 died, 76 CCF NT-proBNP
1,941 pg/ml
predicts CCF or
death; HR: 3.19
pective cohort, mean
llow-up 4.4 yrs
BNP 7 deaths, 11 CCF BNP 31 pg/ml
predicts death
or CCF; HR:
1.09 per 10
pg/ml
evere AS; AS III  very severe AS
ith permission from Weber et al. (60).Pros
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May 11, 2010:2034–48 Natriuretic Peptides in Valvular Heart Diseaseo age, peak and mean gradients, and the presence of CAD.
hey had a slightly smaller AVA and slightly lower LVEF;
owever, by multivariate analysis, only NT-proBNP (p 
.05) and LVEF (p  0.05) were independent predictors of
emaining free of symptoms during follow-up (51).
urvival/major adverse cardiovascular events (MACE).
n an elderly cohort of 124 unoperated patients with
oderate to severe AS, survival was significantly influenced
y the presence of symptoms (relative risk: 7.5, p  0.01)
nd BNP tertile (relative risk: 2.9, p  0.001) (57). The
-year mortality rate without surgery was 6%, 34%, and 60%
ith each increasing tertile. No patients with BNP 100
g/ml died (57). The combination of BNP and symptoms
rovided a better prediction of survival than symptoms
lone (chi-square 13.6, p  0.001) (57). BNP significantly
relative risk: 2.8, p  0.01) influenced survival after
orrection for other univariate predictors: CAD, symptoms,
YHA functional class, LVEF, and AVA (57). Two other
tudies in patients with variable severity of AS, many of
hom had symptoms or in whom symptoms developed but
ere still predominantly managed medically, have also
hown increased mortality or hospitalization with heart
ailure in those with elevated BNP (46) or NT-proBNP
45). In the Weber et al. (45) study of the conservatively
anaged patients with an adverse outcome, only one-third
n  3) had severe AS, and, compared with event-free
urvivors, the prevalence of CAD was almost double and
VEF was significantly lower. In the Antoni-Canterin et al.
46) study, despite 24 patients being of NYHA functional
lasses III to IV, only 2 had AVR (46). These studies are
nlikely to be representative of those patients being followed
erially and being considered for surgery with the develop-
ent of symptoms.
REDICTING MACE INCLUDING AVR. Three relatively small
tudies in patients with asymptomatic mild-severe AS have
hown that those with elevated levels of NT-proBNP are
ore likely to die, be hospitalized, or need AVR due to the
evelopment of symptoms (55,67,68). Weber et al. (61) also
emonstrated that NT-proBNP using an optimized cutoff
f 550 pg/ml is a good indicator (85% accuracy) of the
linician’s decision to refer for AVR in 105 patients with
evere AS, 84 of whom had American College of Cardiol-
gy/American Heart Association indications for surgery.
he group from Vienna also showed that low BNP/
T-proBNP/NT-proANP are predictive of short-term
ymptom-free survival in 43 asymptomatic patients with
evere AS (51), with NT-proBNP having the best discrim-
nation. Monin et al. (69), from France, recently suggested
ncorporating BNP levels into a continuous risk score to
redict MACE (69). The model was developed in 107
atients with moderate to severe AS and incorporated the score
peak velocity (m/s)x2] (natural logarithm of BNP 1.5)
.5 (if female sex), which was subsequently validated in another
07 patients from Belgium. MACE were largely driven by
ositive exercise tests leading to referral for AVR while still Tsymptomatic. Although these studies clearly demonstrate the
otential of BNP/NT-proBNP as useful prognostic markers in
symptomatic AS, they do not give us evidence that operating
n asymptomatic patients with high levels leads to a reduction
n mortality or better functional outcome.
redictors of post-operative outcome. CARDIAC FUNCTION.
n the hours after surgical AVR for AS, there is an increase
n BNP (70) and ANP (71). BNP then decreases signifi-
antly at 6 and 12 months post-AVR but does not return to
ormal (44,61). Decreases occur in parallel with decreases in
ean transvalvular pressure gradient and left ventricular
ass (72), with patients with the largest post-operative
alve area index having the largest decrease in NT-proBNP
73). The fact that BNP levels were still elevated post-
peratively might indicate that BNP is a marker of insuffi-
ient reverse remodeling with ongoing stimulus for BNP
ynthesis. Alternatively, because BNP inhibits myocyte
rowth and fibrosis (74), it may have a more direct role in
he reverse-remodeling process. Mean myocardial systolic
train increases after AVR, which occurs in parallel with
ecreases in LVMI, both of which are independently related
o changes in NT-proBNP (r  0.67, p  0.001; r 
0.71, p  0.001) during 12 months of follow-up after
VR (49). NT-proBNP is a significant predictor of normal
ost-operative LVEF, along with pre-operative LVEF, by
ultivariate analysis (51). Post-operative changes in LA
olume and LA pressure were reflected in ANP (49) and
T-proANP (73) levels, respectively. Persistently high
T-proANP seems to be predictive of late post-operative
trial fibrillation (AF), consistent with high LA pressure
eing an important determinant of AF (75).
YMPTOMS. Three studies demonstrated that high pre-
perative BNP/NT-proBNP levels are associated with de-
reased symptomatic improvement in AS patients (47,51,72).
atients in whom there is no symptomatic improvement tend
o have nonsignificant decreases in NT-proBNP and LVMI
ven though the transvalvular pressure gradient decreases
72). Seventeen of 40 patients with symptomatic AS who
nderwent AVR and in whom symptoms of left-sided heart
ailure, right-sided heart failure, or hypotension developed
n-hospital were characterized by significantly higher
aseline pre-operative BNP levels (399  82 pg/ml vs.
24  41 pg/ml, p  0.011), end-diastolic wall stress,
nd pulmonary capilliary wedge pressure but with similar
everity of AS and systolic function (47).
URVIVAL. Three moderately large studies examined the
rognostic value of BNP/NT-proBNP for survival in oper-
ted patients with severe AS (51,52,72) and a fourth
eported on 70 patients, of whom 43 had AVR (58). Two
tudies showed that NT-proBNP (51) and BNP (52) were
ndependent predictors of perioperative mortality. The lat-
er study also demonstrated the superiority of BNP in the
rediction of perioperative and long-term mortality com-
ared with the commonly used logistic EuroSCORE (52).
hese results tend to be supported by Lim et al. (58),
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Natriuretic Peptides in Valvular Heart Disease May 11, 2010:2034–48lthough the mortality results included death in 7 patients
ho did not have surgery. The 4 patients who did have
VR and died all had increased BNP (58). In contrast,
owever, NT-proBNP was not predictive of survival or
ospitalization for heart failure in 102 patients with severe
S undergoing AVR (45). There is not a clear explanation
hy these results differed but may be related to the lower
requency of concomitant coronary artery bypass graft and
lightly younger age of patients in the Weber et al. (45)
tudy compared with the Pedrazzini et al. (52) study (29%
s. 42% coronary artery bypass graft, 69  10 years vs. 73 
years, respectively).
ow-flow, low-gradient aortic stenosis. BNP is higher in
atients with truly severe compared with pseudosevere AS
nd correlates with AS severity and LVEF (76). BNP was a
trong predictor of outcome. With BNP levels550 pg/ml,
he cumulative 1-year survival rate of the total cohort when
ompared with those with BNP levels 550 pg/ml was
7  9% versus 97  3% (p  0.0001), and the post-
perative survival rate was 53  13% versus 92  7% (76).
hen subdivided into truly severe and pseudosevere AS,
he groups were too small for statistical analysis; however,
consistent pattern of higher mortality was observed in
atients with BNP 550 pg/ml. The poorer survival in
atients with high BNP/NT-proBNP undergoing AVR
oes suggest that those patients may have more irrevers-
ble myocardial dysfunction, which may be directly re-
ated to overt replacement myocardial fibrosis (77).
atriuretic Peptides in MR
linical decision making in MR. MR is the second most
ommon form of valve disease. MR may be divided into
rganic and functional, depending on whether the valve
eaflets or chords themselves are abnormal or whether the
eak reflects an abnormality of the supporting structures. In
he developed world, degenerative valve disease is the most
ommon cause of moderate or severe MR, with endocarditis
nd rheumatic disease making up most of the remainder.
schemic heart disease is the most common cause of
unctional MR. Chronic MR, if sufficiently severe, leads to
olume overload of the left ventricle, which in turn results in
ompensatory chamber dilation and eccentric hypertrophy.
he transition to a decompensated state is poorly under-
tood but might be due to a progressive increase in regur-
itant volume, a decrease in contractility, an increase in
fterload, or a combination of these factors (78). It is usually
ssociated with the onset of symptoms but may be insidious.
he decompensated state is characterized by marked ventric-
lar dilation, increased diastolic pressure, increased systolic wall
tress, and a decrease in ejection fraction to less than 60%. In
ost instances, the management of functional MR is
reating the underlying condition, whereas in organic MR,
herapy is targeted at the specific valvular abnormality.
urrent guidelines for the management of severe organic
R reflect strong evidence that surgical intervention is best terformed before the onset of limiting symptoms or even a
inor reduction in LVEF (35,79,80). Wherever possible,
itral valve repair is a better option than valve replacement
ecause the outcome is superior (35,81). In asymptomatic
atients with normal LVEF, management is less clear. One
pproach is to recommend surgery in patients with proven
evere organic MR on the basis that it is highly likely that
ymptoms or LV dysfunction will develop sooner or later
82); a second approach is to refer for surgery at the first sign
f symptoms, a decline in LV function, onset of AF, or
ncreasing pulmonary arterial pressures (83). As with AS,
he watchful waiting approach may result in patients with
arly symptoms slipping through the net, particularly with-
ut functional testing. Equally, misplaced enthusiasm for
arly surgery might condemn a previously asymptomatic
atient to the hazards of surgery and the far-from-trivial
isks of a failed repair and a mechanical prosthesis. Current
merican College of Cardiology/American Heart Associa-
ion guidelines are explicit in stating that mitral valve repair
n asymptomatic patients should only be attempted if there
s a 90% expectation that a successful repair can be achieved,
nd a surgical mortality rate of 1% and 5-year recurrence
ate of 5% have been suggested as standards in this group
f patients (35,84). Although this might be possible in
xpert centers, it is far from clear that is achievable more
idely. There is no clear evidence that surgical treatment of
unctional MR carries a prognostic benefit.
aseline correlations. COMPARISONS WITH CONTROLS.
here are limited data on levels of natriuretic peptides in
R in comparison with normal controls. In one study of 49
atients with varying degrees of isolated organic MR and an
VEF of 55%, plasma levels of ANP, BNP, and NT-
roBNP were greater in both asymptomatic and symptom-
tic patients with MR compared with controls after adjust-
ent for age, sex, and body surface area (85). A second
tudy of 78 patients with varying degrees of both organic
nd functional MR also found increased ANP and BNP
evels compared with controls (86).
EVERITY OF VALVE DISEASE. There is a variable relation-
hip between plasma levels of natriuretic peptides and the
everity of MR in published studies. A number of studies
emonstrated a positive relationship between natriuretic
eptides and the severity of both organic and functional MR
87–90), whereas others have shown either no correlation
r a relationship only on univariate analysis (86,91–93).
indings are summarized in Table 4. This variability in
ndings likely reflects heterogeneous patient populations,
ut the implication is that natriuretic peptides are not a
linically useful marker of the severity of the regurgita-
ion per se. In practice, this is not a particular issue
ecause the severity of regurgitation can usually be
etermined by echocardiography.
ARDIAC STRUCTURE AND FUNCTION. The majority of
tudies fail to show a significant association between any of
he natriuretic peptides and LVEF (85,86,89–92) (Table 4).
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May 11, 2010:2034–48 Natriuretic Peptides in Valvular Heart Diseasexceptions are a study including patients with organic MR
n which there was a weak negative correlation between
T-proBNP and LVEF (r  0.25) (93) and a study in
hich the BNP/ANP ratio showed a similar finding (94).
imilarly, there is no consistent association with right
entricular function, LV diastolic filling parameters, or
easures of end-diastolic size (86,90,92,93). Increased LV
nd-systolic dimensions or volumes are important markers
f ventricular decompensation in chronic MR and are
ssociated with BNP and NT-proBNP in most but not all
eries (86,89,90,93) as are increased pulmonary arterial
ystolic pressures (86,89,92). The most consistent, but not
niversal, association is with LA dimensions or volumes
85,89,90,92,93). AF was an independent predictor of BNP
evels in one study (91), but another showed that both ANP
nd BNP decreased with very large atria in the presence of
F (94). BNP levels are higher in patients with functional
ompared with organic MR, but this reflects a greater
egree of LV dysfunction with larger end-systolic volumes
nd greater wall stress (86). Stratification for LV end-
ystolic volume index (LVESVI) removed the effect of the
tiology of MR. The concept that BNP provides an inte-
rated index of cardiac remodeling including systolic LV
ilation, LA dilation, and pulmonary hypertension is an
ttractive one but is not supported by all studies. Again, this
s related to the highly heterogeneous patient populations
tudied. Table 6 summarizes findings from 4 studies that
ncluded data on LVESVI. The majority found that BNP
as a marker for increased LVESVI (86,87,90), with the
ne study with negative findings having a small range of
VESVI (92). Thus, BNP is a marker for systolic ventric-
lar remodeling in chronic MR but only in the context of a
ide range of ventricular volumes and hence probably not
seful in identifying the earliest stages of ventricular decom-
ensation. The consistent relationship between BNP and
A size suggests that BNP may be produced by LA
yocardium in response to chronic increases in atrial wall
tress rather than solely by ventricular myocardium (92).
he relationship to pulmonary arterial systolic pressure is
ess easy to explain given the lack of relationship between
NP and measures of right ventricular function.
YMPTOMATIC STATUS. BNP, NT-proBNP, and ANP are
ll higher in symptomatic than asymptomatic patients after
djustment for the severity of MR and the extent of atrial
nd ventricular remodeling (85). A cutpoint of BNP of 12
Data for End-Systolic Volume Index (ml/m2) forOrg nic and Functional MR From 4 Studies DemTable 6 Data f r End-Syst lic Volume Ind xOrganic and Functional MR From 4
First Author (Ref. #) Controls Asym
Detaint et al. (86) 26 5
Kerr et al. (92) 16 6
Yusoff et al. (90)
Dini et al. (87)Abbreviation as in Table 2.mol/l predicted the presence of symptoms with 75%
ensitivity, 85% specificity, and an area under the curve
AUC) of 0.90. AUCs for NT-proBNP and ANP were
oth 0.89, and all were superior to LA size, LV size, and
everity of MR. Similarly, Potocki et al. (93) demonstrated
n AUC of 0.80 for NT-proBNP. Levels of BNP and
T-proBNP increase progressively with worsening symp-
omatic class, albeit with a considerable degree of overlap
86,87,90–93). Shimamoto et al. (94) found that plasma
NP was increased in patients with NYHA functional class
I symptoms but then decreased in those with NYHA
unctional class III and IV symptoms, whereas BNP and
ence the BNP/ANP ratio increased progressively. For
YHA functional class II, III, or IV, a cutpoint for a
NP/ANP ratio of 1.2 gave 88% sensitivity, 83% specificity,
nd an AUC of 0.82. For NYHA functional class III or IV,
cutpoint of 2.97 gave 78% sensitivity, 87% specificity, and
n AUC of 0.86.
ESPONSE TO EXERCISE. Yusoff et al. (90), in a study of 38
atients with severe degenerative MR, identified NT-
roBNP levels as a strong independent predictor of maximal
xygen uptake, whereas there were only weak correlations
etween exercise parameters and resting echocardiographic
ariables. Kerr et al. (92) performed exercise echocardiog-
aphy in 33 patients with moderate to severe or severe MR
nd preserved LVEF at rest. Increased BNP levels were
ssociated with increased pulmonary arterial pressures at rest
nd on exercise and increased LA volumes and lower
unctional capacity on exercise testing, but not with either
esting or exercise measures of LV size and function. The
mplication of these findings is that although resting BNP
evels are clearly related to impaired functional capacity, they
ay not be a marker of the failure of LV contractile reserve
er se.
redictors of outcome. Detaint et al. (91) followed 124
atients with chronic isolated organic MR for a mean of
.4  1.4 years after diagnosis and sampling for BNP. At
iagnosis, 35% had severe MR, 69% were NHYA func-
ional class I, 21% functional class II, and 7% functional
lass III or IV. After adjustment for age, sex, symptoms,
VEF, and severity of MR, BNP was an independent
redictor of survival with a hazard ratio of 1.23 per 10
g/ml. For death or heart failure, the hazard ratio was 1.09
er 10 pg/ml. In an elegant study, Pizarro et al. (89) enrolled
69 patients with severe organic MR and normal results of
rols and Patients Withating Marked Heterogeneitym2) for Controls and Pati nts With
ies Demonstrating Marked Heterogeneity
Organic MR
atic Symptomatic Functional MR
42 14 96 33
26 6
40 10
87 34Contons(ml/
Stud
ptom
27 7
37 9
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Natriuretic Peptides in Valvular Heart Disease May 11, 2010:2034–48readmill exercise testing. The first 167 patients were used as
derivation cohort and the second 102 as a validation
ohort. BNP was assayed on samples taken as baseline and
year, and patients were followed to a combined end point
f death, development of LV systolic dysfunction (LVEF
60%), or the onset of heart failure (NYHA functional
lass III or IV). The AUC for the receiver-operator char-
cteristic curve of BNP as a predictor of the combined end
oint was 0.80 for the derivation cohort and 0.81 for the
alidation cohort. Stratification of baseline BNP into quar-
iles gave event-free survival rates at 48 months of 99%,
7%, 93%, and 29%. Using a cutpoint of 105 pg/ml from
he derivation cohort, the combined end point occurred in
6% of the validation cohort with a BNP 105 pg/ml as
pposed to 4% with a BNP105 pg/ml (p 0.00001) with
hazard ratio of 4.7 on Kaplan-Meier analysis (p 
.0001). In the validation cohort, BNP105 pg/ml was the
trongest independent predictor of the combined end point
OR: 4.1), followed by an effective regurgitant orifice area
55 mm2 (OR: 3.7) and an end-systolic diameter/body
urface area of 22 mm2 (OR: 3.1). In a study of patients
ith functional MR, NT-proBNP 1,941 pg/ml was
econd only to a marked increase in the LVESVI (82
l/m2) as an independent predictor of death, with a hazard
atio of 2.17 (p  0.026), and was the most powerful
redictor of death or hospitalization, with a hazard ratio of
.19 (p  0.001) (87).
onclusions
he role of natriuretic peptides as cardiac hormones is clear
iven their close relationship to cardiac structure and func-
ion, reflecting LV wall stress and subclinical myocardial
ysfunction. In valvular heart disease, they are correlated
ith disease severity, although this is more reliable in AS
han MR, as well as symptomatic status. Determining
ymptomatic status itself can be difficult even with a
igorous clinical history. Breathlessness in particular is very
ubjective; in a large group of elderly people, one-third of
atients were classified as breathless, using the Medical
esearch Council Scale, but only one-half of them had any
dentifiable pathology (95). Natriuretic peptides could play a
ole here. Perhaps the most exciting prospect for future use
omes from their ability to predict outcome. BNP and
T-proBNP show the most promise. In AS, low levels are
ood predictors of symptom-free survival and high levels
re indicative of subsequent mortality, at least in medi-
ally managed patients. High levels may also be strong
redictors of perioperative and long-term mortality. In
R, plasma levels are associated with adverse outcomes
n both organic and functional MR, and there are
reliminary data to suggest that BNP might be a useful
redictor of incipient decompensation in asymptomatic
atients with organic MR.
In both AS and MR, the difficulty remains in deciding onhe optimum timing of surgery in asymptomatic patients. A
1eliable biomarker that appropriately risk-stratifies such
atients would be invaluable. Natriuretic peptides have been
xtensively studied in valvular heart disease, as we have
etailed; however, there are no studies that have tested the
ypothesis that early surgical intervention in asymptomatic
atients with severe valvular heart disease and elevated levels
f natriuretic peptides reduces mortality or improves func-
ional outcome. Additionally, there are many comorbidities
hat are not uncommon in valvular heart disease, such as
AD, diabetes, and hypertension, and their impact on
atriuretic peptide levels has not been clearly established.
hether natriuretic peptides will have a clinically useful
ole is yet to be proven; prospective, randomized, controlled
rials in well-described patient populations are needed
efore they can be incorporated into the routine manage-
ent of these challenging and increasingly prevalent patient
roups.
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